| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited | $23.43 | $23.86B | N/A |
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685884
Dec 24, 2019 - Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
0
Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
http://www.zacks.com/stock/news/678945/teva-pharmaceutical-industries-ltd-teva-outpaces-stock-market-gains-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-678945
Dec 19, 2019 - Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $9.97, moving +1.73% from the previous trading session.
0
Teva Avoids Bankruptcy, Huge Upside
https://seekingalpha.com/article/4313242-teva-avoids-bankruptcy-huge-upside?source=feed_tag_israel
Dec 18, 2019 -
0
Bayer and Teva Double Down on Worst M&A Deals of Decade
http://www.gurufocus.com/news/995213/bayer-and-teva-double-down-on-worst-ma-deals-of-decade
Dec 04, 2019 - Bayer and Teva Double Down on Worst M&A Deals of Decade, Stocks: BAYN,TEVA,GILD,MRK,NVS,BMY,PFE,GSK,SHRS,SNY,AMGN,A, release date:Dec 03, 2019
0
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
http://www.zacks.com/stock/news/653885/jjs-jnj-new-tests-reveal-no-asbestos-in-baby-powders?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-653885
Dec 04, 2019 - J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
0
Why The Bear Attack On Teva Pharmaceutical Must End
https://seekingalpha.com/article/4309342-bear-attack-teva-pharmaceutical-must-end?source=feed_tag_israel
Nov 26, 2019 - Renewed bearishness on Teva over the opioid subpoena may prove short-lived.Third-quarter results a positive inflection point.Business recovery underway.
0
Why The Bear Attack On Teva Pharmaceutical Must End
https://seekingalpha.com/article/4309342-why-bear-attack-on-teva-pharmaceutical-must-end?source=feed_tag_israel
Nov 26, 2019 - Renewed bearishness on Teva over the opioid subpoena may prove short-lived.Third-quarter results a positive inflection point.Business recovery underway.
0
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
http://www.zacks.com/stock/news/641354/generic-drugmakers-gain-as-price-fixing-probe-nears-an-end?cid=CS-ZC-FT-analyst_blog|investment_ideas-641354
Nov 26, 2019 - Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
0
Teva in talks with DoJ to end generics probe - Bloomberg
https://seekingalpha.com/news/3521819-teva-talks-doj-end-generics-probe-bloomberg?source=feed_news_all
Nov 25, 2019 - Teva Pharmaceuticals (TEVA +6.5%) pops higher in morning trade following a Bloomberg report that it has held talks with the U.S. Department of Justice about resolving a criminal antitrust probe of all
0
Teva inks early-stage drug research deals
https://seekingalpha.com/news/3521812-teva-inks-early-stage-drug-research-deals?source=feed_news_all
Nov 25, 2019 - Teva (NYSE:TEVA) is starting the week up 5.6% after signing research agreements with two leading Israeli academic institutes to boost its early-stage drug development.A partnership with Tel Aviv Unive
0